Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
Date:2/17/2009

f HIV and a robust pipeline of HCV programs spanning the three classes of direct-acting antivirals," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix. "As we begin 2009, the recent execution of the license agreement for IDX899 enables us to focus all of our resources on the advancement of our HCV programs, with the goal of having a drug candidate from each of the three major classes of direct-acting antivirals in the clinic."

For the fourth quarter ended December 31, 2008, Idenix reported total revenues of $4.3 million, compared with total revenues of $12.6 million in the fourth quarter of 2007. The decrease was mainly due to $10.1 million in lower reimbursements of research and development costs from Novartis. Idenix reported a net loss of $13.9 million, or a loss of $0.25 per basic and diluted share, for the fourth quarter ended December 31, 2008, compared to a net loss of $17.5 million, or a loss of $0.31 per basic and diluted share for the fourth quarter ended December 31, 2007.

For the twelve months ended December 31, 2008, Idenix reported total revenues of $10.0 million, compared with total revenues of $68.0 million for the twelve months ended December 31, 2007. The majority of the decrease was due to $40.6 million in lower reimbursements of research and development costs from Novartis, a decrease of $10.0 million due to the lack of milestone payments in 2008 as compared to 2007 and $8.0 million due to lower license fee revenue. The company reported a net loss of $70.2 million, or a loss of $1.24 per basic and diluted share for the twelve months ended December 31, 2008, compared with $82.5 million, or a loss of $1.47 per basic and diluted share for the twelve months ended December 31, 2007. The net loss reported for the twelve months ended December 31, 2007 included $8.7 million in restructuring charges, which included the impairment of certain assets equal to approximately $2.1 million.'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... target drug delivery. , ... Cary, NC (PRWEB) October ... company ) and Auburn University announced today a joint research project ... Veterinary Medicine,s Department of Pathobiology, the six-month study is under the ...
... 2008 5:00 p.m. EST, HOPKINTON, Mass., Oct. ... ) will conduct a conference call discussing the,company,s ... EST on Monday,November 10. Kevin Hrusovsky, President and ... will host the call. Management will,discuss operational and ...
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ), a clinical-stage ... novel medicines in the areas of,hepatitis C and ... the third quarter ended September 30, 2008., ... of our hepatitis C,development programs," said Steve Worland ...
Cached Biology Technology:Calvert Research and Auburn University Announce Joint Venture 2Calvert Research and Auburn University Announce Joint Venture 3Caliper Life Sciences' Third Quarter 2008 Financial Results Conference Call Notice 2Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 2Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 3Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 4Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 5Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 6Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 7Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 8
(Date:7/9/2014)... As climate change shifts the geographic ranges in which ... it has on their parasites. Does an increased range ... as well? , Not necessarily, says a team of ... Armand Kuris. In a study published in the ... that for some species, the opposite may happen: Hosts ...
(Date:7/9/2014)... Emerging fungal pathogens pose a greater threat ... population declines of amphibians, bats, corals, bees and ... Florida published in the prestigious journal Nature ... immunological resistance to a deadly chytrid fungus implicated ... resistance is important because it is the basis ...
(Date:7/9/2014)... with traumatic injuries have identified an immune marker ... a hospital-acquired infection. The study, led by clinician-scientists ... June in the journal Shock , is ... to the clinical implementation of quick-turnaround immune function ... system damage following critical illness or injury in ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4USF study: Amphibians can acquire resistance to deadly fungus 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... biologists is figuring out which among the hundreds of genetic ... driving the cancer,s spread. Using a new technique ... that appears to drive progression of small cell lung cancer, ... percent of lung cancer cases. The gene, which ...
... Foundation has awarded Delft University of Technology (TU Delft, the ... project is to develop new technology for processing human waste ... costs affordable to the poor in developing countries. ... at the AfricaSan conference in Rwanda (www.africasan3.com) as part of ...
... Knowing how trees grow and how they age may ... warmer climate, for instance, and other changes. Little is known, ... tree growth. "Although much research has been done on how ... increase in size," says research ecologist Frederick (Rick) Meinzer, "structure ...
Cached Biology News:New lung-cancer gene found 2Reinventing the toilet for safe and affordable sanitation 2
...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... The NEW HandyStep electronic from BRAND ... pipetting. It is the only electronic, ... standard syringe tips, including BRAND PD-Tip ... Plus, Fisherbrand Dispenser Tips,and VWRbrand Combi-Syringes. ...
Biology Products: